Abbott Laboratories stock: At EUR 90.37, stock gains 3.09 percent
Published on 10/22/2026 at 15:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPrice gains 3.09 percent
- BTIG Research cut its target from USD 134.00 to USD 125.00 on October 22, 2026.
- Abbott Laboratories released third-quarter results on October 21, 2026.
- Abbott Laboratories stock costs EUR 90.37 at Lang & Schwarz on October 22, 2026 at 3:41 p.m. CEST, 3.09 percent above the Xetra close of October 21, 2026.
- The next earnings date is January 27, 2027.
Abbott Laboratories (ISIN US0028241000) saw BTIG Research cut its price target from USD 134.00 to USD 125.00 on October 22, 2026, while keeping a Buy rating, according to MarketBeat. Abbott Laboratories was trading at EUR 90.37 at Lang & Schwarz on October 22, 2026 at 3:41 p.m. CEST, up 3.09 percent versus the Xetra close of October 21, 2026 at EUR 87.66.
BTIG target remains above the quote
The reduced BTIG target still stood 24.44 percent above the NYSE price of USD 100.45 at 9:55 a.m. ET on October 22, 2026. That comparison uses the same home-exchange currency and puts the analyst view above the intraday US quote.
The target change also contrasts with the broader analyst picture reported by MarketBeat. The outlet said BTIG retained its Buy rating while lowering the target, keeping the research firm positive on Abbott despite the lower valuation reference.
Stock sits below its yearly high
Abbott Laboratories stock remained 20.28 percent below its EUR 113.36 52-week high and 28.92 percent above its EUR 70.10 52-week low on October 22, 2026. The same Xetra quote showed a market capitalization of EUR 156.7 billion and volume of 415 shares at 3:33 p.m. CEST.
On the NYSE, the stock traded between USD 81.97 and USD 132.03 over the 52 weeks through October 22, 2026. Its market capitalization was USD 173.8 billion, the price-to-earnings ratio was 32.32 and the dividend yield was 0.03 percent at 9:55 a.m. ET.
Valuation meets the next date
Abbott Laboratories released its third-quarter results on October 21, 2026, a date reported by MarketBeat. The next earnings date is January 27, 2027, according to TradingView.
What comes next for investors?
The January reporting date gives the market its next fixed checkpoint. Until then, the key numerical tension is between the USD 125.00 BTIG target, the USD 100.45 NYSE quote and the EUR 90.37 German indication.
Euro quote after the move
Abbott Laboratories was trading at EUR 90.37 at Lang & Schwarz on October 22, 2026 at 3:41 p.m. CEST, 3.09 percent above the Xetra close of October 21, 2026 at EUR 87.66.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories stock at a glance
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 22, 2026, 3:41 p.m. CEST: EUR 90.37
- Change versus Xetra close: plus 3.09 percent
- Xetra close October 21, 2026: EUR 87.66
- Market capitalization: USD 173.8 billion as of October 22, 2026
- 52-week range: EUR 70.10-EUR 113.36 as of October 22, 2026
- Sector / Industry: Healthcare / Medical Devices
- Next earnings date: January 27, 2027
Market context: Market report S&P 500.
